Evidence map›Paper›PMID 27338624›Full record

ArticleDiabetologia2016

CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion.

Mia Abels, Matteo Riva, Hedvig Bennet, Emma Ahlqvist, Oleg Dyachok, Vini Nagaraj, Liliya Shcherbina, Rikard G Fred, Wenny Poon, Maria Sörhede-Winzell and 15 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. A Single Dose ofBrain sciences · 2021
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 3 countries.

Mia AbelsLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Matteo RivaLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Hedvig BennetLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Emma AhlqvistLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Oleg DyachokDepartment of Medical Cell Biology, Uppsala University Biomedical Centre, Uppsala, Sweden.
Vini NagarajLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Liliya ShcherbinaLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Rikard G FredLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Wenny PoonLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Maria Sörhede-WinzellLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Joao FadistaLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Andreas LindqvistLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Lena KaskLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Ramasri SathanooriLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Marloes Dekker-NitertLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Michael J KuharThe Yerkes Research Center of Emory University, Atlanta, GA, USA.
Bo AhrénLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Claes B WollheimDepartment of Cell Physiology and Metabolism, University Medical Centre, Geneva, Switzerland.
Ola HanssonLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Anders TengholmDepartment of Medical Cell Biology, Uppsala University Biomedical Centre, Uppsala, Sweden.
Malin FexLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Erik RenströmLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Leif GroopLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Valeriya LyssenkoLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
Nils WierupLund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden. nils.wierup@med.lu.se.
Skåne University Hospital · SELund University · SEUppsala University · SEEmory University · USSteno Diabetes Center · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisInsufficient insulin release and hyperglucagonaemia are culprits in type 2 diabetes. Cocaine- and amphetamine-regulated transcript (CART, encoded by Cartpt) affects islet hormone secretion and beta cell survival in vitro in rats, and Cart (-/-) mice have diminished insulin secretion. We aimed to test if CART is differentially regulated in human type 2 diabetic islets and if CART affects insulin and glucagon secretion in vitro in humans and in vivo in mice.

methodsCART expression was assessed in human type 2 diabetic and non-diabetic control pancreases and rodent models of diabetes. Insulin and glucagon secretion was examined in isolated islets and in vivo in mice. Ca(2+) oscillation patterns and exocytosis were studied in mouse islets.

resultsWe report an important role of CART in human islet function and glucose homeostasis in mice. CART was found to be expressed in human alpha and beta cells and in a subpopulation of mouse beta cells. Notably, CART expression was several fold higher in islets of type 2 diabetic humans and rodents. CART increased insulin secretion in vivo in mice and in human and mouse islets. Furthermore, CART increased beta cell exocytosis, altered the glucose-induced Ca(2+) signalling pattern in mouse islets from fast to slow oscillations and improved synchronisation of the oscillations between different islet regions. Finally, CART reduced glucagon secretion in human and mouse islets, as well as in vivo in mice via diminished alpha cell exocytosis. CONCLUSIONS/

interpretationWe conclude that CART is a regulator of glucose homeostasis and could play an important role in the pathophysiology of type 2 diabetes. Based on the ability of CART to increase insulin secretion and reduce glucagon secretion, CART-based agents could be a therapeutic modality in type 2 diabetes.

Indexed as

AnimalsBlotting, WesternCalcium SignalingCocaine- and Amphetamine-Regulated Transcript ProteinDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2ElectrophysiologyExocytosisFemaleGlucagonGlucagon-Secreting CellsGlucoseHomeostasisHumansImmunohistochemistryIn Situ HybridizationCocaine- and Amphetamine-Regulated Transcript ProteinGlucagonGlucoseInsulinNerve Tissue ProteinsCART peptideCocaine- and amphetamine-regulated transcriptGlucagonInsulinIsletsType 2 diabetes

Identifiers

PMID27338624
OpenAlexW2467104390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.